Dealing with these decisions isn’t easy while undergoing cancer treatment. But yes, it’s completely understandable to ...

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

Prostate cancer is a significant health concern for men worldwide, with increasing diagnoses and fatalities projected. Early ...

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year ...

A genetics research laboratory has reached a significant milestone in its efforts to recruit 1,000 volunteers for a prostate ...

Belgium: Janssen-Cilag International NV, a Johnson & Johnson company, has announced the submission of an extension of ...

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

He identified age as the leading risk factor, noting that cases are rarely seen in men under 40. Genetics and family history ...

OUR resident specialist and NHS GP, Dr Zoe Williams, shares her expert advice. Today, Dr Zoe helps a reader who is concerned ...

Australians aged in their 30s and 40s are experiencing unprecedented and in some cases world-leading rates of 10 different ...

Australians in their 30s and 40s are being diagnosed with cancer at unprecedented rates, with at least 10 types of the ...

Department of Urology is seeing 50-60 prostate cancer patients daily, with most being men aged 45 and above. Dr. Porferio ...